Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.
Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.